WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 522387
CAS#: 376640-41-4
Description: BVT-2733 is a selective 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor, which attenuates obesity and inflammation in diet-induced obese mice. BVT-2733 protects osteoblasts against endogenous glucocorticoid induced dysfunction. BVT-2733 exhibits an anti-inflammatory effect on CIA. This protective effect is, at least partly, mediated by inhibition of the NF-κB and NLRP1 inflammasome signaling pathways. 11β-Hydroxysteroid dehydrogenase 1 (11β-HSD1) plays an important role in inflammation. 11β-HSD1 inhibition may represent a potential therapeutic target for RA patients.
MedKoo Cat#: 522387
Name: BVT-2733
CAS#: 376640-41-4
Chemical Formula: C17H21ClN4O3S2
Exact Mass: 428.07436
Molecular Weight: 428.95
Elemental Analysis: C, 47.60; H, 4.93; Cl, 8.26; N, 13.06; O, 11.19; S, 14.95
BVT-2733, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Synonym: BVT-2733; BVT 2733; BVT2733; BVT.2733
IUPAC/Chemical Name: 3-chloro-2-methyl-N-(4-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)thiazol-2-yl)benzenesulfonamide
InChi Key: YDPRNGAPPNPYQQ-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H21ClN4O3S2/c1-12-14(18)4-3-5-15(12)27(24,25)20-17-19-13(11-26-17)10-16(23)22-8-6-21(2)7-9-22/h3-5,11H,6-10H2,1-2H3,(H,19,20)
SMILES Code: CN1CCN(C(CC2=CSC(NS(=O)(C3=CC=CC(Cl)=C3C)=O)=N2)=O)CC1
The following data is based on the product molecular weight 428.95 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Zhang L, Dong Y, Zou F, Wu M, Fan C, Ding Y. 11β-Hydroxysteroid dehydrogenase 1 inhibition attenuates collagen-induced arthritis. Int Immunopharmacol. 2013 Nov;17(3):489-94. doi: 10.1016/j.intimp.2013.07.015. Epub 2013 Aug 11. PubMed PMID: 23938253.
2: Wu L, Qi H, Zhong Y, Lv S, Yu J, Liu J, Wang L, Bi J, Kong X, Di W, Zha J, Liu F, Ding G. 11β-Hydroxysteroid dehydrogenase type 1 selective inhibitor BVT.2733 protects osteoblasts against endogenous glucocorticoid induced dysfunction. Endocr J. 2013;60(9):1047-58. Epub 2013 Jun 12. PubMed PMID: 23759754.
3: Liu J, Kong X, Wang L, Qi H, Di W, Zhang X, Wu L, Chen X, Yu J, Zha J, Lv S, Zhang A, Cheng P, Hu M, Li Y, Bi J, Li Y, Hu F, Zhong Y, Xu Y, Ding G. Essential roles of 11β-HSD1 in regulating brown adipocyte function. J Mol Endocrinol. 2013 Jan 11;50(1):103-13. doi: 10.1530/JME-12-0099. Print 2013 Feb. PubMed PMID: 23197361.
4: Wang L, Liu J, Zhang A, Cheng P, Zhang X, Lv S, Wu L, Yu J, Di W, Zha J, Kong X, Qi H, Zhong Y, Ding G. BVT.2733, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, attenuates obesity and inflammation in diet-induced obese mice. PLoS One. 2012;7(7):e40056. doi: 10.1371/journal.pone.0040056. Epub 2012 Jul 2. PubMed PMID: 22768329; PubMed Central PMCID: PMC3388048.
5: Liu J, Wang L, Zhang A, Di W, Zhang X, Wu L, Yu J, Zha J, Lv S, Cheng P, Hu M, Li Y, Qi H, Ding G, Zhong Y. Adipose tissue-targeted 11β-hydroxysteroid dehydrogenase type 1 inhibitor protects against diet-induced obesity. Endocr J. 2011;58(3):199-209. Epub 2011 Feb 17. PubMed PMID: 21325744.
6: Xie Y, Zhu T, Zhong Y, Liu J, Yu J, Zha JM, DI WJ, Ding GX. [Mechanism of BVT.2733 and pioglitazone in the improvement of insulin resistance]. Zhonghua Nei Ke Za Zhi. 2008 Nov;47(11):938-41. Chinese. PubMed PMID: 19080239.
7: Richards S, Sorensen B, Jae HS, Winn M, Chen Y, Wang J, Fung S, Monzon K, Frevert EU, Jacobson P, Sham H, Link JT. Discovery of potent and selective inhibitors of 11beta-HSD1 for the treatment of metabolic syndrome. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6241-5. Epub 2006 Sep 26. PubMed PMID: 17000111.
8: Wang SJ, Birtles S, de Schoolmeester J, Swales J, Moody G, Hislop D, O'Dowd J, Smith DM, Turnbull AV, Arch JR. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice. Diabetologia. 2006 Jun;49(6):1333-7. Epub 2006 Apr 13. PubMed PMID: 16612591.
9: Hult M, Shafqat N, Elleby B, Mitschke D, Svensson S, Forsgren M, Barf T, Vallgårda J, Abrahmsen L, Oppermann U. Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons. Mol Cell Endocrinol. 2006 Mar 27;248(1-2):26-33. Epub 2006 Jan 20. PubMed PMID: 16431016.
10: Alberts P, Nilsson C, Selen G, Engblom LO, Edling NH, Norling S, Klingström G, Larsson C, Forsgren M, Ashkzari M, Nilsson CE, Fiedler M, Bergqvist E, Ohman B, Björkstrand E, Abrahmsen LB. Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology. 2003 Nov;144(11):4755-62. Epub 2003 Jul 31. PubMed PMID: 12960099.
11: Alberts P, Engblom L, Edling N, Forsgren M, Klingström G, Larsson C, Rönquist-Nii Y, Ohman B, Abrahmsén L. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia. 2002 Nov;45(11):1528-32. Epub 2002 Sep 18. PubMed PMID: 12436336.
